Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC

Immunotherapy has revolutionized the treatment of many cancer types. However, pancreatic ductal adenocarcinomas (PDACs) exhibit poor responses to immune checkpoint inhibitors with immunotherapy-based trials not generating convincing clinical activity. PDAC tumors often have low infiltration of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cattolico, Carlotta, Bailey, Peter, Barry, Simon T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902310/
https://www.ncbi.nlm.nih.gov/pubmed/35273962
http://dx.doi.org/10.3389/fcell.2022.816517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902310/
https://www.ncbi.nlm.nih.gov/pubmed/35273962
http://dx.doi.org/10.3389/fcell.2022.816517

Ejemplares similares